TheraRadar
← Back
Data updated: Jun 28, 2026

CHIESI

Big Pharma
RespiratoryCardiovascularDermatology Execution: Good

CHIESI is a major pharmaceutical company focused on Respiratory, Cardiovascular, Dermatology. Key products include KENGREAL.

1988
Since
16
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
8 Small Molecules

FDA Novel Drug Designations

(2023)
1 Novel 1 First-in-Class 1 Orphan 1 Priority Review 1 Fast Track
See 1 novel approval →
2023 FILSUVEZ (BIRCH TRITERPENES) First-in-Class · Orphan · Priority Review · Fast Track

CHIESI at a Glance

  • Fast trial execution (12 months median completion)

CHIESI's Key Drugs

CHIESI's core commercial portfolio centers on KENGREAL, BETHKIS, FILSUVEZ, spanning Respiratory and Cardiovascular — its most strategically important drugs approved in the last 15 years.

KENGREAL
Cardiovascular

Myocardial Infarction

P2Y12 Approved 2015
BETHKIS
Respiratory

Cystic Fibrosis

Approved 2012
FILSUVEZ
Dermatology

Epidermolysis Bullosa

Approved 2023
MYCAPSSA
Endocrine

Acromegaly

Somatostatin receptor Approved 2020
FERRIPROX
Rare Disease
Approved 2011

CHIESI's Recent FDA Approvals

CHIESI secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

TRIMBOW NDA
2026-05-14
beclomethasone dipropionate

CHIESI's Therapeutic Areas

CHIESI's approved drugs and pipeline span 5 therapeutic areas, led by Respiratory and Cardiovascular, across 0 biologic and 8 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Respiratory 87%
1 drugs Phase 3: 32 Phase 2: 39 Phase 1: 39
Cardiovascular 10%
4 drugs Phase 3: 1
Dermatology 1%
0 drugs Phase 3: 1
Neurology 1%
0 drugs Phase 2: 2
Gastroenterology 0%
0 drugs Phase 1: 1

CHIESI Pipeline Snapshot

CHIESI has 115 active clinical programs from ClinicalTrials.gov — 34 Phase 3, 41 Phase 2 and 40 Phase 1.

34
Phase 3
41
Phase 2
40
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • KENGREAL leads revenue
  • • 5 key drugs tracked
View revenue breakdown →

Trial Catalysts

  • • Respiratory pipeline focus
  • • Phase 3 readout tracking
View full pipeline →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →

Execution Intelligence

  • • Phase 3: 31/44 completed
  • • Speed: 12 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges